消栓肠溶胶囊复合降纤酶治疗糖尿病并发心脑血管疾病的疗效  

Therapeutic Effect of Xiaoshuan Enteric-coated Capsule Combined with Defibrase on Diabetes Complicated with Cardiovascular and Cerebrovascular Diseases

作　　者：刘翔 朱俊 林海燕 沈馨茹[2] 鲁佳 许小明 敖锋 LIU Xiang;ZHU Jun;LIN Haiyan;SHEN Xinru;LU Jia;XU Xiaoming;AO Feng(Department of Endocrinology,Maanshan General Hospital of Ranger-Duree Healthcare,Maanshan 243000,China;Department of Endocrinology,Maanshan People′s Hospital,Maanshan 243000,China;Department of Endocrinology,Maanshan Shiqiye Hospital,Maanshan 243000,China;School of Pharmacy,Hubei University of Medicine,Shiyan 442000,China)

机构地区：[1]德驭医疗马鞍山总医院内分泌科,马鞍山243000 [2]马鞍山市人民医院内分泌科,马鞍山243000 [3]马鞍山市十七冶医院内分泌科,马鞍山243000 [4]湖北省医药学院药学部,十堰442000

出　　处：《世界中医药》2023年第18期2656-2660,共5页World Chinese Medicine

基　　金：湖北省教育厅科学研究计划项目(B2017114)。

摘　　要：目的:研究消栓肠溶胶囊联合降纤酶治疗2型糖尿病合并心脑血管疾病的疗效及对炎症介质的影响。方法:选取2020年2月至2022年3月德玉医疗中心马鞍山总医院收治的2型糖尿病合并心脑血管疾病患者80例作为研究对象,按照简单随机化随机分为对照组和观察组,每组40例,对照组给予降纤酶治疗,观察组采用消栓肠溶胶囊联合降纤酶治疗,比较2组的临床疗效,治疗前后的全血黏度、纤维蛋白原(FIB)、血小板聚集率(PAG)、脑循环动力学、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)以及不良反应情况。结果:观察组治疗有效率92.5%大于对照组治疗有效率75.0%(P<0.05);治疗后,对照组和观察组的全血低、中、高切黏度,FIB,PAG均有显著下降,且观察组效果优于对照组(P<0.05);治疗后,观察组和对照组炎症介质水平均有显著下降,且观察组下降更显著(P<0.05);治疗后,2组的平均血流速和血流量均较治疗前增加,外周阻力、脑血管床特性阻抗水平均较治疗前降低,且观察组降低更显著(P<0.05);2组的不良反应发生率比较差异无统计学意义(P>0.05)。结论:消栓肠溶胶囊联合降纤酶治疗2型糖尿病合并心脑血管疾病疗效显著,治疗安全性高,值得临床推广与应用。Objective:To study the therapeutic effect of Xiaoshuan Enteric-Coated Capsule combined with defibrase in the treatment of type 2 diabetes with cardiovascular and cerebrovascular diseases and the influence on inflammatory factors.Methods:Eighty patients with type 2 diabetes combined with cardiovascular and cerebrovascular diseases admitted to Maanshan General Hospital of of Ranger-Duree Healthcare from Feburary 2020 to March 2022 were selected and divided into control group and observation group according to the simple randomization method,40 cases in each group.The control group was given defibrase,while the observation group was given Xiaoshuan enteric-coated capsule combined with defibrase.The clinical efficacy of the two groups was compared.The whole blood viscosity,fibrinogen(FIB),platelet aggregation(PAG)rate,cerebral circulation,tumor necrosis factor-α(TNF-α),interleukin 6(IL-6)and adverse reactions were compared between the two groups before and after treatment.Results:The clinical efficacy of patients in the observation group was 92.5%,higher than 75%in the control group(P<0.05).After treatment,the whole blood viscosity at low,medium and high shear rates,FIB and PAG rate of patients in the two groups were significantly reduced,and the observation group had better effects than the control group(P<0.05).Both groups had decreased inflammatory factors,and the observation group was more significant(P<0.05).The mean blood flow velocity and blood flow increased in both groups after treatment,and the peripheral resistance and cerebrovascular impedance decreased compared with the conditions before treatment,and the indexes were all more significant in the observation group(P<0.05).There was no significant difference in the incidence of adverse reactions in the two groups(P>0.05).Conclusion:Xiaoshuan Enteric-Coated Capsule combined with defibrase is effective in the treatment of patients with type 2 diabetes with cardiovascular and cerebrovascular diseases and has high safety,which is worthy of clinical promotion

关 键 词：消栓肠溶胶囊 降纤酶 2型糖尿病 合并心脑血管疾病 全血黏度 纤维蛋白原 血小板聚集率 脑循环动力学 炎症介质 

分 类 号：R289.5[医药卫生—方剂学] R587.2[医药卫生—中药学]